Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
RANCHO CORDOVA, Calif., Feb. 26, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the commercial launch of its AXP II system for the advanced isolation, collection and storage of hematopoietic stem cell concentrates from cord blood and peripheral blood.
“Since its introduction in 2006, our AXP system has been viewed as the gold standard in the volume reduction processing of cord blood, and we count many of the world’s leading public and private cord blood banks among our current long-time customers,” said Chris Xu, PhD, chief executive officer of Cesca Therapeutics. “Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry. With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK® software that together represent the biggest advancement in automated cord blood processing in many years. With the commercial launch of AXP II, we are continuing to fulfill our commitment to provide the highest quality, most innovative products to the cord blood bank market.”
AXP II is a complete, automated and functionally closed system that includes the AXP II device, docking station, processing set, and XpressTRAK software that maintains compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.
For more information, please visit: www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
